Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer.

Mosig RA, Lobl M, Senturk E, Shah H, Cohen S, Chudin E, Fruscio R, Marchini S, D'Incalci M, Sachidanandam R, Dottino P, Martignetti JA.

J Ovarian Res. 2012 Jan 20;5(1):3. doi: 10.1186/1757-2215-5-3.

2.

High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.

Lancaster JM, Sayer RA, Blanchette C, Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg DW, Marks JR, Berchuck A.

Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1529-35.

PMID:
16884361
3.

Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer.

Baron-Hay S, Boyle F, Ferrier A, Scott C.

Clin Cancer Res. 2004 Mar 1;10(5):1796-806.

4.

[The expressions and clinical significance of IGFBP-2, -3 in both serum and tumor tissues in patients with epithelial ovarian cancer].

Yan XJ, Tian Y, Wang C, Wang XL, Di JM, Cheng JX.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2009 Jul;40(4):639-43. Chinese.

PMID:
19764562
5.

Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.

Serin IS, Tanriverdi F, Yilmaz MO, Ozcelik B, Unluhizarci K.

Gynecol Endocrinol. 2008 Mar;24(3):117-21. doi: 10.1080/09513590801895559.

PMID:
18335323
6.

Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.

7.

Validation of candidate serum ovarian cancer biomarkers for early detection.

Su F, Lang J, Kumar A, Ng C, Hsieh B, Suchard MA, Reddy ST, Farias-Eisner R.

Biomark Insights. 2007 Oct 16;2:369-75.

8.

Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.

Zheng H, Gao Y.

Int J Gynecol Cancer. 2012 Jul;22(6):1000-5. doi: 10.1097/IGC.0b013e318249bee7.

PMID:
22426406
9.
11.

Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence.

Yu H, Nicar MR, Shi R, Berkel HJ, Nam R, Trachtenberg J, Diamandis EP.

Urology. 2001 Mar;57(3):471-5.

PMID:
11248622
12.

[The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].

Dong L, Chang XH, Ye X, Zhu LR, Zhao Y, Tian L, Cheng HY, Li XP, Zhang H, Liao QP, Fu TY, Cheng YX, Cui H.

Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):931-6. Chinese.

PMID:
19134334
13.

Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A [corrected].

Mathur SP, Mathur RS, Gray EA, Lane D, Underwood PG, Kohler M, Creasman WT.

Gynecol Oncol. 2005 Sep;98(3):467-83. Erratum in: Gynecol Oncol. 2006 Apr;101(1):186.

PMID:
15982726
14.

Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.

Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):129-37.

15.

HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.

Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN.

Asian Pac J Cancer Prev. 2010;11(1):111-6.

16.

Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.

Ahmed N, Oliva KT, Barker G, Hoffmann P, Reeve S, Smith IA, Quinn MA, Rice GE.

Proteomics. 2005 Nov;5(17):4625-36.

PMID:
16220531
17.
18.

[Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF].

Zhao Q, Duan W, Wu YM, Qian XH, Deng XH.

Zhonghua Zhong Liu Za Zhi. 2008 Oct;30(10):754-8. Chinese.

PMID:
19173805
19.

Increased levels of insulin-like growth factor binding protein-2 in sera and tumours from patients with colonic neoplasia with and without acromegaly.

Miraki-Moud F, Jenkins PJ, Fairclough PD, Jordan S, Bustin SA, Jones AM, Lowe DG, Monson JP, Grossman AB, Besser GM, Camacho-Hübner C.

Clin Endocrinol (Oxf). 2001 Apr;54(4):499-508.

PMID:
11318786
20.
Items per page

Supplemental Content

Write to the Help Desk